MW 391.5 Da, Purity >99%. Synthetic retinoid agonist. Anticancer, apoptotic, antioxidant activity in vitro and in vivo. Demonstrates a long half-life in vivo.
Images
Publications
- Carcinogenesis 33:1098-1052012Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: a strategy to reintroduce fenretinide for oral cancer chemoprevention.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAndrew S Holpuch,Maynard P Phelps,Kashappa-Goud H Desai,Wei Chen,George M Koutras,Byungdo B Han,Blake M Warner,Ping Pei,Garrett A Seghi,Meng Tong,Michael B Border,Henry W Fields,Gary D Stoner,Peter E Larsen,Zhongfa Liu,Steven P Schwendeman,Susan R MalleryPubMed 22427354
- Apoptosis : an international journal on programmed cell death 11:1677-942006Mechanisms of fenretinide-induced apoptosis.Applications:Unspecified applicationReactive species:Unspecified reactive speciesN Hail,H J Kim,R LotanPubMed 16850162
Key facts
- CAS number
65646-68-6
- Purity
> 99%
- Form
Solid
- Molecular weight
391.5 Da
- Molecular formula
C26H33NO2
- PubChem identifier
5288209
- Nature
Synthetic
Target data
Alternative names
1,8-cineole 2-exo-monooxygenase, 3-dioxygenase 2, 3-dioxygenase-like protein 1, A830040C14Rik, ACEE, ACES_HUMAN, ACLS, AHDC, AI838772, AIS, ALDC, ALDH 1, ALDH 11, ALDH class 1, ALDH class 2, ALDH-E1, ALDH-E2, ALDHI, ALDM, ALHDII, ANDR_HUMAN, APOPAIN, AR, AR8, ARACHE, ARO, ARO1, AW493413, Acetaldehyde dehydrogenase 1, Acetaldehyde dehydrogenase 2, Acetylcholinesterase, Albendazole monooxygenase, Albendazole sulfoxidase, Aldehyde dehydrogenase 1, Aldehyde dehydrogenase 1 family member A1, Aldehyde dehydrogenase 1 soluble, Aldehyde dehydrogenase 1A1, Aldehyde dehydrogenase 2 family, Aldehyde dehydrogenase 2 family (mitochondrial), Aldehyde dehydrogenase cytosolic, Aldehyde dehydrogenase liver cytosolic, Aldehyde dehydrogenase mitochondrial, Aldh, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Apoptosis related acetylcholinesterase, Apoptotic protease Mch-3, Aromatase, Atherosclerosis, susceptibility to, included, BCC7, BXR, C-mpl ligand, CASP3_HUMAN, CASP7_HUMAN, CBX, CBX1_HUMAN, CC3, CMH-1, CMT1A, CMT1E, CP19A_HUMAN, CP33, CP34, CP3A4_HUMAN, CPP-32, CPP32B, CPV1, CRBP, CRBP-I, CRBP1, CRBP2, CYAR, CYP19, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, CYPXIX, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase 7, Caspase 7 apoptosis related cysteine peptidase, Caspase-3, Caspase-3 subunit p12, Caspase-7 subunit p11, Cellular retinol-binding protein, Cellular retinol-binding protein I, Cellular tumor antigen p53, Chromobox 1, Chromobox homolog 1 (HP1 beta homolog Drosophila ), Chromobox protein homolog 1, Cyp19a1, Cysteine protease CPP32, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), Cytochrome P450-PCN1, Cytosolic NADP-isocitrate dehydrogenase, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Drosophila HP1 beta, EC 1.13.11., EC 3.4.22.56, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Epididymis luminal protein 216, Epididymis secretory protein Li 26, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, FK506 binding protein 12 rapamycin associated protein 1, FK506 binding protein 12 rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, FLJ11090, FLJ44809, FLJ92943, FRAP, FRAP1, FRAP2, GAS-3, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, Glucocorticoid inducible P450, Growth Arrest Specific 3, Growth arrest-specific protein 3, HD 7, HD 7B, HD 9, HDAC, HDAC 7B, HDAC 9B, HDAC 9FL, HDAC9_HUMAN, HDL cholesterol, augmented response of, to hormone replacement, included, HDRP, HEL-216, HEL-S-26, HLP, HMSNIA, HNPP, HP1 beta, HP1 beta homolog, HP1 beta homolog Drosophila, HP1, Drosophila. homolog of, beta, HP1Hs beta, HUMARA, HYSP1, Heterochromatin protein 1 beta, Heterochromatin protein 1 homolog beta, Heterochromatin protein p25, Histone deacetylase 4/5 related protein, Histone deacetylase 7, Histone deacetylase 7B, Histone deacetylase 9, Histone deacetylase 9A, Histone deacetylase-related protein, Human heterochromatin protein p25 mRNA complete cds, I23O2_HUMAN, ICDH, ICE-LAP3, ICE-like apoptotic protease 3, ICE3, IDCD, IDH, IDH1, IDHC_HUMAN, IDO-2, IDP, IDPC, IMD42, INDOL 1, Indoleamine 2, Indoleamine 2,3 dioxygenase 2, Indoleamine 2,3 dioxygenase like 1 protein, Indoleamine 2,3 dioxygenase like protein 1, Indoleamine pyrrole 2,3 dioxygenase like 1, Indoleamine pyrrole 2,3 dioxygenase like protein 1, Indoleamine-pyrrole 2, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, KD, KIAA0744, Kennedy disease (KD), LFS1, LICE, LICE2, Liver mitochondrial ALDH, M31, MCH3, MEF2 interacting transcription repressor protein, MEF2-interacting transcription repressor MITR, MGC104252, MGC104309, MGC112732, MGC126680, MGC129539, MGC1806, MGC20769, MGC2318, MGDF, MITR, MKCSF, MOD 1, MPL ligand, MPLLG, MTOR_HUMAN, Mammalian target of rapamycin, Mechanistic target of rapamycin, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, Megakaryocyte stimulating factor, Microsomal monooxygenase, Mitochondrial aldehyde dehydrogenase 2, Modifier 1 protein, Mutant tumor protein 53, Myeloproliferative leukemia virus oncogene ligand, Myocardial infarction, susceptibility to, included, N-ACHE, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, NF 25, NR1B1, NR1C3, NR1F3, NR1I2_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, Nucleus encoded mitochondrial aldehyde dehydrogenase 2, ONR 1, OTTHUMP00000001983, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000162543, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, OTTHUMP00000198350, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Oncogene GLI3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, Oxalosuccinate decarboxylase, P 450AROM, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, PAP A, PAPB, PAR, PAR q, PARP cleavage protease, PICD, PMP22_HUMAN, PPAR-gamma, PPARG2, PPARG_HUMAN, PPD IV, PRR, PUMB 1, Peripheral myelin protein 22, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Pregnane X receptor, Procaspase3, Protein Yama, Quinine 3-monooxygenase, RAFT1, RALDH 1, RAPT1, RAR, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-alpha, RAR-related orphan receptor C, RARA_HUMAN, RARalpha1, RBPC, RET1_HUMAN, RNESTROR, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Rapamycin and FKBP12 target 1, Rapamycin associated protein FRAP2, Rapamycin target protein, Rapamycin target protein 1, Retinal dehydrogenase 1, Retinaldehyde dehydrogenase 1, Retinoic acid binding receptor gamma, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid-related orphan receptor-gamma, Retinol binding protein 1 cellular, Retinol binding protein 2 cellular, Retinol binding protein 4 plasma, Retinol-binding protein 1, Rorc, SBMA, SCA-1, SCAN1, SMAX1, SREBP cleavage activity 1, SXR, Serine/threonine-protein kinase mTOR, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TFM, THCYT1, TOR, TRP53, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Thrombopoietin, Thrombopoietin nirs variant 1, Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Trembler, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, YT, YT blood group, Yama, Yama protein, Zinc finger protein GLI 3, androgen receptor splice variant 4b, chromobox homolog 1, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1), estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, heterochromatin protein p25 beta, mldy, p25beta, p53 tumor suppressor, pregnane X nuclear receptor variant 2, tumor antigen p55
Recommended products
MW 391.5 Da, Purity >99%. Synthetic retinoid agonist. Anticancer, apoptotic, antioxidant activity in vitro and in vivo. Demonstrates a long half-life in vivo.
Alternative names
1,8-cineole 2-exo-monooxygenase, 3-dioxygenase 2, 3-dioxygenase-like protein 1, A830040C14Rik, ACEE, ACES_HUMAN, ACLS, AHDC, AI838772, AIS, ALDC, ALDH 1, ALDH 11, ALDH class 1, ALDH class 2, ALDH-E1, ALDH-E2, ALDHI, ALDM, ALHDII, ANDR_HUMAN, APOPAIN, AR, AR8, ARACHE, ARO, ARO1, AW493413, Acetaldehyde dehydrogenase 1, Acetaldehyde dehydrogenase 2, Acetylcholinesterase, Albendazole monooxygenase, Albendazole sulfoxidase, Aldehyde dehydrogenase 1, Aldehyde dehydrogenase 1 family member A1, Aldehyde dehydrogenase 1 soluble, Aldehyde dehydrogenase 1A1, Aldehyde dehydrogenase 2 family, Aldehyde dehydrogenase 2 family (mitochondrial), Aldehyde dehydrogenase cytosolic, Aldehyde dehydrogenase liver cytosolic, Aldehyde dehydrogenase mitochondrial, Aldh, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Apoptosis related acetylcholinesterase, Apoptotic protease Mch-3, Aromatase, Atherosclerosis, susceptibility to, included, BCC7, BXR, C-mpl ligand, CASP3_HUMAN, CASP7_HUMAN, CBX, CBX1_HUMAN, CC3, CMH-1, CMT1A, CMT1E, CP19A_HUMAN, CP33, CP34, CP3A4_HUMAN, CPP-32, CPP32B, CPV1, CRBP, CRBP-I, CRBP1, CRBP2, CYAR, CYP19, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, CYPXIX, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase 7, Caspase 7 apoptosis related cysteine peptidase, Caspase-3, Caspase-3 subunit p12, Caspase-7 subunit p11, Cellular retinol-binding protein, Cellular retinol-binding protein I, Cellular tumor antigen p53, Chromobox 1, Chromobox homolog 1 (HP1 beta homolog Drosophila ), Chromobox protein homolog 1, Cyp19a1, Cysteine protease CPP32, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), Cytochrome P450-PCN1, Cytosolic NADP-isocitrate dehydrogenase, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Drosophila HP1 beta, EC 1.13.11., EC 3.4.22.56, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Epididymis luminal protein 216, Epididymis secretory protein Li 26, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, FK506 binding protein 12 rapamycin associated protein 1, FK506 binding protein 12 rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, FLJ11090, FLJ44809, FLJ92943, FRAP, FRAP1, FRAP2, GAS-3, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, Glucocorticoid inducible P450, Growth Arrest Specific 3, Growth arrest-specific protein 3, HD 7, HD 7B, HD 9, HDAC, HDAC 7B, HDAC 9B, HDAC 9FL, HDAC9_HUMAN, HDL cholesterol, augmented response of, to hormone replacement, included, HDRP, HEL-216, HEL-S-26, HLP, HMSNIA, HNPP, HP1 beta, HP1 beta homolog, HP1 beta homolog Drosophila, HP1, Drosophila. homolog of, beta, HP1Hs beta, HUMARA, HYSP1, Heterochromatin protein 1 beta, Heterochromatin protein 1 homolog beta, Heterochromatin protein p25, Histone deacetylase 4/5 related protein, Histone deacetylase 7, Histone deacetylase 7B, Histone deacetylase 9, Histone deacetylase 9A, Histone deacetylase-related protein, Human heterochromatin protein p25 mRNA complete cds, I23O2_HUMAN, ICDH, ICE-LAP3, ICE-like apoptotic protease 3, ICE3, IDCD, IDH, IDH1, IDHC_HUMAN, IDO-2, IDP, IDPC, IMD42, INDOL 1, Indoleamine 2, Indoleamine 2,3 dioxygenase 2, Indoleamine 2,3 dioxygenase like 1 protein, Indoleamine 2,3 dioxygenase like protein 1, Indoleamine pyrrole 2,3 dioxygenase like 1, Indoleamine pyrrole 2,3 dioxygenase like protein 1, Indoleamine-pyrrole 2, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, KD, KIAA0744, Kennedy disease (KD), LFS1, LICE, LICE2, Liver mitochondrial ALDH, M31, MCH3, MEF2 interacting transcription repressor protein, MEF2-interacting transcription repressor MITR, MGC104252, MGC104309, MGC112732, MGC126680, MGC129539, MGC1806, MGC20769, MGC2318, MGDF, MITR, MKCSF, MOD 1, MPL ligand, MPLLG, MTOR_HUMAN, Mammalian target of rapamycin, Mechanistic target of rapamycin, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, Megakaryocyte stimulating factor, Microsomal monooxygenase, Mitochondrial aldehyde dehydrogenase 2, Modifier 1 protein, Mutant tumor protein 53, Myeloproliferative leukemia virus oncogene ligand, Myocardial infarction, susceptibility to, included, N-ACHE, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, NF 25, NR1B1, NR1C3, NR1F3, NR1I2_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, Nucleus encoded mitochondrial aldehyde dehydrogenase 2, ONR 1, OTTHUMP00000001983, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000162543, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, OTTHUMP00000198350, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Oncogene GLI3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, Oxalosuccinate decarboxylase, P 450AROM, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, PAP A, PAPB, PAR, PAR q, PARP cleavage protease, PICD, PMP22_HUMAN, PPAR-gamma, PPARG2, PPARG_HUMAN, PPD IV, PRR, PUMB 1, Peripheral myelin protein 22, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Pregnane X receptor, Procaspase3, Protein Yama, Quinine 3-monooxygenase, RAFT1, RALDH 1, RAPT1, RAR, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-alpha, RAR-related orphan receptor C, RARA_HUMAN, RARalpha1, RBPC, RET1_HUMAN, RNESTROR, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Rapamycin and FKBP12 target 1, Rapamycin associated protein FRAP2, Rapamycin target protein, Rapamycin target protein 1, Retinal dehydrogenase 1, Retinaldehyde dehydrogenase 1, Retinoic acid binding receptor gamma, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid-related orphan receptor-gamma, Retinol binding protein 1 cellular, Retinol binding protein 2 cellular, Retinol binding protein 4 plasma, Retinol-binding protein 1, Rorc, SBMA, SCA-1, SCAN1, SMAX1, SREBP cleavage activity 1, SXR, Serine/threonine-protein kinase mTOR, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TFM, THCYT1, TOR, TRP53, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Thrombopoietin, Thrombopoietin nirs variant 1, Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Trembler, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, YT, YT blood group, Yama, Yama protein, Zinc finger protein GLI 3, androgen receptor splice variant 4b, chromobox homolog 1, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1), estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, heterochromatin protein p25 beta, mldy, p25beta, p53 tumor suppressor, pregnane X nuclear receptor variant 2, tumor antigen p55
Key facts
- CAS number
65646-68-6
- Purity
> 99%
- Form
Solid
- Molecular weight
391.5 Da
- Molecular formula
C26H33NO2
- PubChem identifier
5288209
- Nature
Synthetic
- Solubility
Soluble in ethanol to 100 mM. Soluble in DMSO to 100 mM.
- Biochemical name
Fenretinide
- Biological description
Synthetic retinoid agonist. Anticancer, apoptotic, antioxidant activity in vitro and in vivo. Demonstrates a long half-life in vivo.
- Canonical SMILES
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C
- Isomeric SMILES
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C
- InChI
InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
- InChIKey
AKJHMTWEGVYYSE-FXILSDISSA-N
- IUPAC name
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate long-term storage conditions
-20°C
- Storage information
It is important to note that this product is reported to be light sensitive, Store in the dark, Store under desiccating conditions
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - Fenretinide, Synthetic retinoid agonist (ab141026)
2D chemical structure image of ab141026, Fenretinide, Synthetic retinoid agonist
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com